Overview
FOXO4-DRI is classified as a senolytic peptide peptide. Senescent cell elimination (senolytics), longevity, tissue rejuvenation, SASP reduction.
D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. In normal cells, FOXO4 retains p53 in the nucleus preventing apoptosis — a mechanism senescent cells exploit for survival. FOXO4-DRI competitively binds FOXO4, freeing p53 to migrate to mitochondria, triggering apoptosis selectively in senescent cells. Results in clearance of senescent cell burden, reduction of the senescence-associated secretory phenotype (SASP), and tissue rejuvenation markers in aged mice.
Also known as: FOXO4-D-Retro-Inverso, Senolytic peptide
Category
Senolytic Peptide
Half-Life
2h
Route
SubQ
FDA Status
Not Approved
How Does FOXO4-DRI Work?
D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. In normal cells, FOXO4 retains p53 in the nucleus preventing apoptosis — a mechanism senescent cells exploit for survival. FOXO4-DRI competitively binds FOXO4, freeing p53 to migrate to mitochondria, triggering apoptosis selectively in senescent cells. Results in clearance of senescent cell burden, reduction of the senescence-associated secretory phenotype (SASP), and tissue rejuvenation markers in aged mice.
At the molecular level, FOXO4-DRI operates through pathways characteristic of the Senolytic Peptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
Safety Profile
⚠ EXPERIMENTAL COMPOUND. NO HUMAN CLINICAL TRIALS. Mechanism is potent and irreversible (apoptosis induction). Selective for senescent cells in mouse models but human selectivity profiles are unknown. Aggressive Herxheimer-like inflammatory response from SASP release possible during senescent cell clearance. DO NOT USE without comprehensive medical supervision.
| Side Effect | Incidence | Severity |
|---|---|---|
| SASP inflammatory response | Unknown in humans | moderate |
| Unknown off-target apoptosis | Unknown | rare |
Sourcing FOXO4-DRI for Research
If you're looking to source FOXO4-DRI for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
FOXO4-DRI — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.